Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy

World Journal of Gastroenterology

Volumn 10, Issue 6, 2004, Pages 910-912

  Su, Guan Guan ^a   Pan, Kong Han ^a   Zhao, Nian Feng ^b   Fang, Su Hua ^a   Yang, Dan Hong ^a   Zhou, Yong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ACTIVE IMMUNIZATION; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FETUS; FETUS DEATH; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PREGNANCY; HISTOPATHOLOGY; HUMAN; INFANT; INFECTION RISK; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEDICAL RECORD; NEWBORN; NEWBORN HYPOXIA; NONHUMAN; PREGNANCY COMPLICATION; PREMATURITY; PRENATAL DIAGNOSIS; SPONTANEOUS ABORTION; VERTICAL TRANSMISSION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

EID: 1842482970     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i6.910     Document Type: Article

References (22)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990; 8: S18-20
2. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496
3. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859
4. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979; 3: 237-241
5. Xu ZY, Liu CB, Francis DP, Purcell RH, Gun ZL, Duan SC, Chen RJ, Margolis HS, Huang CH, Maynard JE. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985; 76: 13-18
6. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983; 147: 185-190
7. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-1635
8. Yang H, Chen R, Li Z, Zhou G, Zhao Y, Cui D, Li S, Han C, Yang L. Analysis of fetal distress in pregnancy with hepatitis B virus infection. Zhonghua Fuchanke Zazhi 2002; 37: 211-213
9. Khuroo MS, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat 2003; 10: 61-69
10. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989; 1: 406-410
11. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, Gerards LJ, de Gast GC, Fetter WP, Zwijneberg J, Schalm SW. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: Protective efficacy and long-term immunogenicity. Vaccine 1997; 15: 1624-1630
12. Faucher P, Batallan A, Bastian H, Matheron S, Morau G, Madelenat P, Benifla JL. Management of pregnant women infected with HIV at Bichat Hospital between 1990 and 1998: analysis of 202 pregnancies. Gynecol Obstet Fertil 2001; 29: 211-225
13. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-297
14. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KH, Stone C, Plumb R, Johnson MA. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-1333
15. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41-66
16. Van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000; 32: 1040-1041
17. Branch society of Infectious Disease and Parasitology and Branch society of Hepatology of Chinese Medical Association. National Preventiont and Treatment Profiles of Viral Hepatitis (2000). Zhonghua Chuanranbing Zazhi 2001; 19: 56-62
18. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
19. Gao SZ. Research on prevention and treatment of viral hepatitis. Beijing: Beijing pub 1993: 38-46, 286-291
20. Expert team for lamivudine clinical use. The year 2000 guideline for lamivudine clinical use. Zhonghua Ganzangbing Zazhi 2000; 8: 249-250
21. Expert team for lamivudine clinical use. Expert consensus on lamivudine clinical use (2001). Zhonghua Ganzangbing Zazhi 2002; 10: 157-158
22. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-639